Robert Higginson

We’re developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. This addresses the significant unmet need for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience.

Senient Cloud Platform is designed for efficiency. It is a breakthrough in simplicity, dependability and scalability. We integrate with your existing infrastructure, yet offers a completely unique design that effectively reduces Total Cost of Ownership (TCO) by up to 85%. Senient Systems builds the most efficient cloud hosting infrastructure on the market. Our team is comprised of industry experts, bring years of real world experience and innovation to our products.

Simple Audio was founded in 2008 by a group of senior designers and engineers who set out to transform the way we listen to music in the home today. Why? Simple. We believe that nothing should come between you and the music you love. We set out to create a system that would deliver the very best quality audio possible, not only now, but in the future. A system that would be simple to use and simple to set up; scalable too and capable of meeting one person's music needs, or that of an entire family home. What's more, it would be an affordable high resolution sound system without a high end price tag, so everyone would be able to benefit from the wonderful depth and richness of sound in their own home. We designed the Roomplayer to change things for the better. Our first Roomplayer was released in 2012 and it quickly gained a reputation for its superior sound performance. In 2013, we received backing from Corsair, which gave us the support we needed to release a new generation Roomplayer. The all-new Roomplayer+ was launched in 2014. We're not short of experience and today, our team operates from Scotland improving the Roomplayer experience daily. That's the beauty of music streaming really. Things change all the time, and we're working to make sure we deliver the best and most enjoyable musical experience possible. Follow us on: Twittter: @simpleaud Facebook: facebook.com/simpleaudio

PXN Group is the combination of two of the North’s best fund managers (Praetura Ventures and Par Equity) coming together to create an investor that the region deserves. With offices in Manchester, Edinburgh, Leeds and London, we deliver world-class investment programmes – including EIS, VCT, Business Relief, Natural Capital and later-stage capital – at scale to help build the Northern economy. We support ambitious founders via our PXN Ventures brand and financial advisers & investors via PXN Investments, which are both brands in the PXN Group. In addition to raising and investing private capital, PXN Group is trusted by a long list of institutions, including the British Business Bank (via its NPIF II fund and Regional Angels programme), Bruntwood SciTech and various combined local authorities. www.pxngroup.co.uk

We’re developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. This addresses the significant unmet need for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience.

Manus Neurodynamica is revolutionising health care management by developing and patenting neuroscience technologies that record recognised biomarkers of neuromotor impairments which can radically improve patient diagnosis and disease monitoring. Our disruptive technology has potential to be used across applications such as screening, rehabilitation and drug development and medicine optimisation, streamlining referrals, reducing costs and increasing the efficiency of specialist services. We are looking for interested researchers, clinicians and practitioners to collaborate in situ assessment and testing of the NeuroMotor pen, as well as investors for the further development of our projects in the EU and US. Our principal product, the NeuroMotor Pen, is a non-invasive, patented medical device that offers earlier-diagnosis and monitoring of neuromotor disorders. Combined with analytical software, the NeuroMotor Pen, processes a patients’ movement parameters, by analysing minute limb and hand motion to quantify fine motor skills and motion features. These motion features are used as "biomarkers" to provide objective information to clinicians about movement abnormalities and this innovative technology can streamline secondary care referrals, reduce costs and increase the efficiency of specialist neuromotor services.

Manus Neurodynamica is revolutionising health care management by developing and patenting neuroscience technologies that record recognised biomarkers of neuromotor impairments which can radically improve patient diagnosis and disease monitoring. Our disruptive technology has potential to be used across applications such as screening, rehabilitation and drug development and medicine optimisation, streamlining referrals, reducing costs and increasing the efficiency of specialist services. We are looking for interested researchers, clinicians and practitioners to collaborate in situ assessment and testing of the NeuroMotor pen, as well as investors for the further development of our projects in the EU and US. Our principal product, the NeuroMotor Pen, is a non-invasive, patented medical device that offers earlier-diagnosis and monitoring of neuromotor disorders. Combined with analytical software, the NeuroMotor Pen, processes a patients’ movement parameters, by analysing minute limb and hand motion to quantify fine motor skills and motion features. These motion features are used as "biomarkers" to provide objective information to clinicians about movement abnormalities and this innovative technology can streamline secondary care referrals, reduce costs and increase the efficiency of specialist neuromotor services.

Senient Cloud Platform is designed for efficiency. It is a breakthrough in simplicity, dependability and scalability. We integrate with your existing infrastructure, yet offers a completely unique design that effectively reduces Total Cost of Ownership (TCO) by up to 85%. Senient Systems builds the most efficient cloud hosting infrastructure on the market. Our team is comprised of industry experts, bring years of real world experience and innovation to our products.